Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 64-69

  Sekine, Akimasa ^a   Kato, Terufumi ^a   Hagiwara, Eri ^a   Shinohara, Takeshi ^a   Komagata, Takanobu ^a   Iwasawa, Tae ^a   Satoh, Hiroaki ^b   Tamura, Katsumi ^c   Kasamatsu, Tomotaka ^c   Hayashihara, Kenji ^c   Saito, Takefumi ^c   Takahashi, Hiroshi ^a   Ogura, Takashi ^a  

^a Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Center of Chest Diseases and Severe Motor and Intellectual Disabilities   (Japan)

Author keywords

Brain edema; Brain metastases; EGFR; Exon 19; Lung cancer; Miliary; Mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ARTICLE; BRAIN CANCER; BRAIN EDEMA; BRAIN METASTASIS; CANCER SIZE; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PRIORITY JOURNAL; RADIOGRAPHY;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; EDEMA; EXONS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEQUENCE DELETION; TUMOR BURDEN;

EID: 84861748432     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.12.017     Document Type: Article

References (33)

1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
2. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
3. Stinchcombe T.E., Lee C.B., Socinski M.A. Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. Clin Lung Cancer 2006, 7:111-117.
4. Sorensen J.B., Hansen H.H., Hansen M., Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988, 6:1474-1480.
5. Zabel A., Milker-Zabel S., Thilmann C., Zuna I., Rhein B., Wannenmacher M., et al. Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors. Lung Cancer 2002, 37:87-94.
6. Mehta M.P., Rodrigus P., Terhaard C.H., Rao A., Suh J., Roa W., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529-2536.
7. Hotta K., Kiura K., Ueoka H., Tabata M., Fujiwara K., Kozuki T., et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004, 46:255-261.
8. Chiu C.H., Tsai C.M., Chen Y.M., Chiang S.C., Liou J.L., Perng R.P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005, 47:129-138.
9. Namba Y., Kijima T., Yokota S., Niinaka M., Kawamura S., Iwasaki T., et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004, 6:123-128.
10. Lee Y.J., Park I.K., Park M.S., Choi H.J., Cho B.C., Chung K.Y., et al. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol 2009, 135:1647-1654.
11. Ogawa M., Kurahashi K., Ebina A., Kaimori M., Wakabayashi K. Miliary brain metastasis presenting with dementia: progression pattern of cancer metastases in the cerebral cortex. Neuropathology 2007, 27:390-395.
12. Ruppert A.M., Stankoff B., Lavole A., Gounant V., Milleron B., Seilhean D. Miliary brain metastases in lung cancer. J Clin Oncol 2010, 28:e714-e716.
13. Iguchi Y., Mano K., Goto Y., Nakano T., Nomura F., Shimokata T., et al. Miliary brain metastases from adenocarcinoma of the lung: MR imaging findings with clinical and post-mortem histopathologic correlation. Neuroradiology 2007, 49:35-39.
14. Laack E., Simon R., Regier M., Andritzky B., Tennstedt P., Habermann C., et al. Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. J Thorac Oncol 2011, 6:199-202.
15. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
16. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
17. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-8923.
18. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
19. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
20. Gilbert J.J., Paulseth J.E., Coates R.K., Malott D. Cerebral edema associated with meningiomas. Neurosurgery 1983, 12:599-605.
21. Tamiya T., Ono Y., Matsumoto K., Ohmoto T. Peritumoral brain edema in intracranial meningiomas: effects of radiological and histological factors. Neurosurgery 2001, 49:1046-1051.
22. Simis A., Pires de Aguiar P.H., Leite C.C., Santana P.A., Rosemberg S., Teixeira M.J. Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol 2008, 70:471-477.
23. Tung G.A., Julius B.D., Rogg J.M. MRI of intracerebral hematoma: value of vasogenic edema ratio for predicting the cause. Neuroradiology 2003, 45:357-362.
24. Zheng Z., Bepler G., Cantor A., Haura E.B. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest 2005, 128:308-316.
25. Ricciardi S., de Marinis F. Multimodality management of non-small cell lung cancer patients with brain metastases. Curr Opin Oncol 2010, 22:86-93.
26. Kim J.E., Lee D.H., Choi Y., Yoon D.H., Kim S.W., Suh C., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009, 65:351-354.
27. Gow C.H., Chien C.R., Chang Y.L., Chiu Y.H., Kuo S.H., Shih J.Y., et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008, 14:162-168.
28. Serizawa T., Hirai T., Nagano O., Higuchi Y., Matsuda S., Ono J., et al. Gamma knife surgery for 1-10 brain metastases without prophylactic whole-brain radiation therapy: analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria. J Neurooncol 2010, 98:163-167.
29. Sundstrom J.T., Minn H., Lertola K.K., Nordman E. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 1998, 30:296-299.
30. Herman S.T. Epilepsy after brain insult: targeting epileptogenesis. Neurology 2002, 59:21-26.
31. van Breemen M.S., Wilms E.B., Vecht C.J. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007, 6:421-430.
32. Kalikaki A., Koutsopoulos A., Trypaki M., Souglakos J., Stathopoulos E., Georgoulias V., et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008, 99:923-929.
33. Gow C.H., Chang Y.L., Hsu Y.C., Tsai M.F., Wu C.T., Yu C.J., et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009, 20:696-702.